Naoki Shirafuji

ORCID: 0000-0001-8484-7724
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Immune Response and Inflammation
  • Chronic Myeloid Leukemia Treatments
  • Mesenchymal stem cell research
  • Retinoids in leukemia and cellular processes
  • Immune Cell Function and Interaction
  • Blood disorders and treatments
  • Lymphoma Diagnosis and Treatment
  • RNA Interference and Gene Delivery
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Polyomavirus and related diseases
  • Neutropenia and Cancer Infections
  • Angiogenesis and VEGF in Cancer
  • Acute Lymphoblastic Leukemia research
  • Bone and Joint Diseases
  • Viral-associated cancers and disorders
  • Eosinophilic Disorders and Syndromes
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Cytomegalovirus and herpesvirus research
  • Parvovirus B19 Infection Studies
  • Transplantation: Methods and Outcomes
  • Protein Degradation and Inhibitors
  • Vascular Tumors and Angiosarcomas
  • T-cell and B-cell Immunology

Teikyo University
2012-2022

Weatherford College
2020-2021

Creative Commons
2020

The University of Tokyo
1989-2005

Fuchu Hospital
2005

Metropolitan Hospital
2005

Metropolitan Hospital Center
2005

University of Tokyo Health Sciences
2004

Tokyo University of Science
1989-2003

Kanazawa University
2003

Prostaglandin (PG) D2 is the most abundant prostanoid produced in central nervous system of mammals and has been implicated modulation neural functions such as sleep induction, nociception, regulation body temperature, odor responses. We generated gene-knockout mice for lipocalin-type PGD2 synthase (L-PGDS) found that intrathecal administration PGE2, an endogenous pain-producing substance, failed to elicit allodynia (touch-evoked pain), which one typical phenomenon neuropathic pain, whereas...

10.1073/pnas.96.2.726 article EN Proceedings of the National Academy of Sciences 1999-01-19

Summary. We performed a clinical comparison of unrelated cord blood transplantation (UCBT) and bone marrow in adult acute leukaemia patients complete remission (CR) who received the same conditioning regimen, graft‐versus‐host disease (GvHD) prophylaxis supportive treatment. The incidence GvHD was almost between two groups, but haematopoietic recovery delayed chronic higher UCBT group. probability 2 year disease‐free survival similar groups. These results suggest that CR without suitable...

10.1046/j.1365-2141.2002.03650.x article EN British Journal of Haematology 2002-07-01

To evaluate whether rescue with cord blood transplantation (CBT) could improve the poor survival after graft failure (GF), we surveyed data of 80 adult patients (median age, 51 years) who received CBT within 3 months GF (primary 64, secondary 16), fludarabine-based reduced-intensity regimens or without melphalan, busulfan, cyclophosphamide, and/or 2-4 Gy total-body irradiation (TBI). A median number 2.4 × 10(7)/kg total nucleated cells (TNC) were infused, and among 61 evaluable survived for...

10.1016/j.bbmt.2010.09.005 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2010-09-17

RUNX 1 is essential for definitive hematopoiesis and T ‐cell differentiation. It has been shown that phosphorylated at specific serine threonine residues by several kinase families. However, it remains unclear whether phosphorylation absolutely required its biological functions. Here, we evaluated hematopoietic activities of mutants with ( S )/threonine ) to alanine A ), aspartic acid D or glutamic E mutations sites using primary culture systems. Consistent the results knockin mice, 1‐2 ,...

10.1002/eji.201040746 article EN European Journal of Immunology 2012-04-01

Seven adult patients with myelodysplastic syndrome (MDS)-related secondary acute myeloid leukaemia (AML) were treated total body irradiation (TBI), cytosine arabinoside (Ara-C) and cyclophosphamide (CY), followed by unrelated human leucocyte antigen (HLA)-mismatched cord blood transplantation (CBT). Granulocyte colony-stimulating factor (G-CSF) was infused continuously from 12 h before until the end of Ara-C therapy to enhance antileukaemia effect Ara-C. Five are alive free disease at 7-31...

10.1046/j.1365-2141.2001.03049.x article EN British Journal of Haematology 2001-09-01

The expression of granulocyte colony-stimulating factor (G-CSF) mRNA was studied in human non-hematopoietic tumors, including 18 cases lung cancers 10 stomach cancers, three glioblastomas, and one case each breast phyllode sarcoma, thyroid cancer, hepatocellular carcinoma. Northern blot analysis detected G-CSF two the cancer cases, glioblastoma both sarcoma carcinoma cases. Since receptors were not on tumor cells by 125I-G-CSF binding assay, autocrine loop are probably involved growth these...

10.3109/08977199009003675 article EN Growth Factors 1990-01-01

Abstract Pulmonary alveolar proteinosis (PAP) is a heterogeneous disease that occasionally develops with hematological malignancy. However, PAP in association hematopoietic stem cell transplantation quite rare. Here we present the first report of patient who developed after cord blood (CBT). A 45‐year‐old female AML underwent unrelated CBT. On day +2 CBT she congestive heart failure diffuse infiltrates bilateral lungs. Despite treatment, further increased progression multiple organ (MOF)....

10.1002/ajh.10107 article EN American Journal of Hematology 2002-05-29

Abstract The promoter region of the liver/bone/kidney-type alkaline phosphatase gene was examined to define cis-acting regulatory sequences and transcription factors responsible for its expression in hematopoietic cells. Transient transfection experiments revealed that regions deleted up -154 base pairs upstream from initiation site had significant activities induce bacterial chloramphenicol acetyltransferase gene. shortest DNA fragment found contain three GC boxes addition a TATA box....

10.1189/jlb.68.5.772 article EN Journal of Leukocyte Biology 2000-11-01

In order to elucidate the mechanism of hyperuricemia in hematologic malignancies, we have retrospectively investigated uric acid metabolism 418 chemotherapy-naïve patients with malignancies. Hyperuricemia was present 116 (27.8%) these on initial hospitalization. Among 65 hyperuricemic analyzed metabolism, six (9.2%) had overproduction type, 52 (80.0%) underexcretion and seven (10.8%) a mixed type. Fourteen (3.3%) developed tumor lysis syndrome patients.

10.1080/15257770.2013.872274 article EN Nucleosides Nucleotides & Nucleic Acids 2014-04-04
Coming Soon ...